Interestingly, a study that evaluated EGFR inhibition as a means to prime tumor vasculature for efficient delivery of chemotherapy showed that in glioblastoma patients, a 2-day pulse of high dose (5,250 mg/day) lapatinib given through twice daily dosing was well tolerated [17]. The gene discussed is EGFR; the disease is glioblastoma.